Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition and Innovation Act of 2009 : Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 12, 2018
April 24, 2020
154bca51-03bf-47a8-8b5d-81c56ff9454a
Related Documents
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry
Guidance DocumentDecember 19, 2018Center for Drug Evaluation and Research
The “Deemed to be a License” Provision of the BPCI Act: Questions and Answers : Guidance for Industry
Guidance DocumentMarch 4, 2020Center for Drug Evaluation and Research
Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs: Guidance for Industry
Guidance DocumentDecember 7, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.